¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"afferent pathways"¿¡ ´ëÇÑ °æºÏ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°³»°úÇб³½Ç »çÀü ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
¼³¸í
C afferent
C ±¸½É ½Å°æ
°¡´Â ½Å°æ ¼¶À¯. Àü´Þ ¼Óµµ°¡ ºü¸£°í ÅëÁõÀ» Àü´ÞÇÑ´Ù.
C primary afferent nociceptor
C ÀÏÂ÷ ±¸½É¼º Ä§ÇØ ¼ö¿ëü, C ÀÏÂ÷ ±¸½É¼º À¯ÇØ ¼ö¿ë±â
converging afferent interneuron
ÁýÇÕ¼º ±¸½É¼º °³Àç ´º·±
cutaneous afferent
ÇǺΠ±¸½É ½Å°æ
inhibitory afferent input
¾ïÁ¦¼º ±¸½É¼º ÀÔ·Â
myelinated afferent
À¯¼öÃÊ ±¸½É ½Å°æ
myelinated afferent inhibition
À¯¼öÃÊ ±¸½É¼º ¾ïÁ¦
myelinated cutaneous afferent
À¯¼öÃÊ ÇǺΠ±¸½É ½Å°æ
myelinated non-nociceptive afferent
À¯¼öÃÊ ºñÄ§ÇØ¼ö¿ë¼º ±¸½É ½Å°æ, À¯¼öÃÊ ºñÀ¯Çؼö¿ë¼º ±¸½É ½Å°æ
myelinated primary afferent
ÀÏÂ÷ À¯¼öÃÊ ±¸½É ½Å°æ
nociceptive afferent input
Ä§ÇØ ¼ö¿ë¼º ±¸½É ÀÔ·Â, À¯ÇØ ¼ö¿ë¼º ±¸½É ÀÔ·Â
nociceptive primary afferent
Ä§ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ½Å°æ, À¯ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ½Å°æ
non-nociceptive A delta C primary afferent
ºñÄ§ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ, ºñÀ¯ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ
non-nociceptive myelinated afferent
ºñÄ§ÇØ ¼ö¿ë¼º À¯¼ö ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º À¯¼ö ±¸½É ¼¶À¯
non-nociceptive myelinated primary afferent
ºñÄ§ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
¼³¸í
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½